VivaVision Biotech
PrivateLast Round
Series D
Extension
May 6, 2023
Total Funding Raised
$60.33M
Momentum Score
25 /100
Company Overview
VivaVision Biotech is a clinical-stage pharmaceutical company that develops best-in-class and first-in-class therapies for ocular diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Revenue Share
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
VivaVision Biotech Comps
Public and private peers based on sector, stage, and business model.
VivaVision Biotech Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D Extension | May 6, 2023 | ||||
| Series D | Apr 19, 2021 |
VivaVision Biotech Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| V-Capital | Series D Extension |
| Viva Biotech | Series D |
| HongShan | Series D |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 3, 2026
Monthly visitors increased 54% MoM.
- Jul 12, 2025
Dr. Quan Dong Nguyen joins the Scientific Advisory Board.
VivaVision Biotech Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about VivaVision Biotech's valuation, stock price, and market status.
